Adverse Events from the Treatment of Parkinson's Disease

Edwards, 1991, Gastrointestinal symptoms in Parkinson's disease, Mov Disord, 6, 151, 10.1002/mds.870060211 Koller, 1998, Mechanism of action of dopaminergic agents in Parkinson's disease, Neurology, 50, S11, 10.1212/WNL.50.6_Suppl_6.S11 Agid, 1979, Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease, Lancet, 1, 570, 10.1016/S0140-6736(79)91003-1 Pollak, 1981, Therapie, 36, 671 Langdon, 1986, Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease, Clin Neuropharmacol, 9, 440, 10.1097/00002826-198610000-00004 Kolls, 2006, Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease, Clin Neuropharmacol, 29, 292, 10.1097/01.WNF.0000220824.57769.E5 Ahlskog, 2001, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord, 16, 448, 10.1002/mds.1090 Schrag, 2006, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, Lancet Neurol, 5, 355, 10.1016/S1474-4422(06)70411-2 Grandas, 1999, Risk factors for levodopa-induced dyskinesias in Parkinson's disease, J Neurol, 246, 1127, 10.1007/s004150050530 Pechevis, 2005, Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study, Eur J Neurol, 12, 956, 10.1111/j.1468-1331.2005.01096.x Fabbrini, 2007, Levodopa-induced dyskinesias, Mov Disord, 22, 1379, 10.1002/mds.21475 Muenter, 1977, Patterns of dystonia in response to L-Dopa therapy for Parkinson's disease, Mayo Clin Proc, 52, 163 Pahwa, 2006, Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 66, 983, 10.1212/01.wnl.0000215250.82576.87 Goetz, 2005, Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004, Mov Disord, 20, 523, 10.1002/mds.20464 Luginger, 2000, Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease, Mov Disord, 15, 873, 10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I Metman, 1999, Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study, Arch Neurol, 56, 1383, 10.1001/archneur.56.11.1383 Snow, 2000, The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study, Clin Neuropharmacol, 23, 82, 10.1097/00002826-200003000-00004 Thomas, 2004, Duration of amantadine benefit on dyskinesia of severe Parkinson's disease, J Neurol Neurosurg Psychiatry, 75, 141 Verhagen Metman, 1998, Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease, Neurology, 50, 1323, 10.1212/WNL.50.5.1323 Durif, 2004, Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study, Neurology, 62, 381, 10.1212/01.WNL.0000110317.52453.6C Bonifati, 1994, Buspirone in levodopa-induced dyskinesias, Clin Neuropharmacol, 17, 73, 10.1097/00002826-199402000-00008 Goetz, 2007, Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial, Mov Disord, 22, 179, 10.1002/mds.21226 Deep Brain Stimulation for Parkinson's Disease Study Group, 2001, Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease, N Engl J Med, 345, 956, 10.1056/NEJMoa000827 Visser-Vandewalle, 2003, Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease, J Neurosurg, 99, 701, 10.3171/jns.2003.99.4.0701 Kleiner-Fisman, 2006, Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes, Mov Disord, 21, S290, 10.1002/mds.20962 Arnulf, 2000, Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis, Neurology, 55, 281, 10.1212/WNL.55.2.281 Factor, 1990, Sleep disorders and sleep effect in Parkinson's disease, Mov Disord, 5, 280, 10.1002/mds.870050404 Van Hilten, 1993, Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease, J Neural Transm Park Dis Dement Sect, 5, 235, 10.1007/BF02257678 Brodsky, 2003, Sleepiness in Parkinson's disease: a controlled study, Mov Disord, 18, 668, 10.1002/mds.10429 Henderson, 2003, Olfactory deficits and sleep disturbances in Parkinson's disease: a case control survey, J Neurol Neurosurg Psychiatry, 74, 956, 10.1136/jnnp.74.7.956 Hogl, 2003, Increased daytime sleepiness in Parkinson's disease: a questionnaire survey, Mov Disord, 18, 319, 10.1002/mds.10365 Arnulf, 2002, Parkinson's disease and sleepiness: an integral part of PD, Neurology, 58, 1019, 10.1212/WNL.58.7.1019 Fabbrini, 2002, Excessive daytime sleepiness in de novo and treated Parkinson's disease, Mov Disord, 17, 1026, 10.1002/mds.10193 O'Suilleabhain, 2002, Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease, Arch Neurol, 59, 986, 10.1001/archneur.59.6.986 Hobson, 2002, Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group, JAMA, 287, 455, 10.1001/jama.287.4.455 Razmy, 2004, Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists, Arch Neurol., 61, 97, 10.1001/archneur.61.1.97 Avorn, 2005, Sudden uncontrollable somnolence and medication use in Parkinson disease, Arch Neurol, 62, 1242, 10.1001/archneur.62.8.1242 Gjerstad, 2006, Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?, Neurology, 67, 853, 10.1212/01.wnl.0000233980.25978.9d Gjerstad, 2007, Insomnia in Parkinson's disease: frequency and progression over time, J Neurol Neurosurg Psychiatry., 78, 476, 10.1136/jnnp.2006.100370 Thornton, 1980, The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man, Psychopharmacology (Berl), 70, 163, 10.1007/BF00435308 Dhawan, 2006, The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography, J Neurol Sci, 248, 158, 10.1016/j.jns.2006.05.004 Kumar, 2002, Sleep disorders in Parkinson's disease, Mov Disord, 17, 775, 10.1002/mds.10167 Poewe, 2004, Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease, Neurology, 63, S12, 10.1212/WNL.63.8_suppl_3.S12 Diederich, 2005, Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients, Mov Disord, 20, 1413, 10.1002/mds.20624 Aarsland, 1999, Range of neuropsychiatric disturbances in patients with Parkinson's disease, J Neurol Neurosurg Psychiatry, 67, 492, 10.1136/jnnp.67.4.492 Tandberg, 1996, The occurrence of depression in Parkinson's disease. A community-based study, Arch Neurol, 53, 175, 10.1001/archneur.1996.00550020087019 Mayeux, 1992, A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender, Arch Neurol, 49, 492, 10.1001/archneur.1992.00530290076015 Aarsland, 1999, Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study, Arch Neurol, 56, 595, 10.1001/archneur.56.5.595 Parkinson Study Group, 2000, Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial, JAMA, 284, 1931, 10.1001/jama.284.15.1931 Rascol, 2000, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group, N Engl J Med, 342, 1484, 10.1056/NEJM200005183422004 Watts, 2007, Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease, Neurology, 68, 272, 10.1212/01.wnl.0000252355.79284.22 Frucht, 1999, Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole, Neurology, 52, 1908, 10.1212/WNL.52.9.1908 Homann, 2002, Sleep attacks in patients taking dopamine agonists: review, BMJ, 324, 1483, 10.1136/bmj.324.7352.1483 Olanow, 2000, Waking up to sleep episodes in Parkinson's disease, Mov Disord, 15, 212, 10.1002/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6 Paus, 2003, Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease, Mov Disord, 18, 659, 10.1002/mds.10417 Meindorfner, 2005, Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel, Mov Disord, 20, 832, 10.1002/mds.20412 Van den Kerchove, 1993, Sustained-release levodopa in parkinsonian patients with nocturnal disabilities, Acta Neurol Belg, 93, 32 Hjort, 2004, Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus, Mov Disord, 19, 196, 10.1002/mds.10639 Adler, 2003, Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease, Mov Disord, 18, 287, 10.1002/mds.10390 Hogl, 2002, Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial, Sleep, 25, 905, 10.1093/sleep/25.8.62 Ondo, 2005, Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial, J Neurol Neurosurg Psychiatry, 76, 1636, 10.1136/jnnp.2005.065870 Voon, 2007, Medication-related impulse control and repetitive behaviors in Parkinson disease, Arch Neurol, 64, 1089, 10.1001/archneur.64.8.1089 Klos, 2005, Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy, Parkinsonism Relat Disord, 11, 381, 10.1016/j.parkreldis.2005.06.005 Voon, 2006, Prevalence of repetitive and reward-seeking behaviors in Parkinson disease, Neurology, 67, 1254, 10.1212/01.wnl.0000238503.20816.13 Voon, 2006, Prospective prevalence of pathologic gambling and medication association in Parkinson disease, Neurology, 66, 1750, 10.1212/01.wnl.0000218206.20920.4d Friedman, 1994, Punding on levodopa, Biol Psychiatry, 36, 350, 10.1016/0006-3223(94)90636-X Avanzi, 2006, Prevalence of pathological gambling in patients with Parkinson's disease, Mov Disord, 21, 2068, 10.1002/mds.21072 Grosset, 2006, Problematic gambling on dopamine agonists: Not such a rarity, Mov Disord, 21, 2206, 10.1002/mds.21110 Weintraub, 2006, Association of dopamine agonist use with impulse control disorders in Parkinson disease, Arch Neurol, 63, 969, 10.1001/archneur.63.7.969 Evans, 2004, Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome, Mov Disord, 19, 397, 10.1002/mds.20045 Miyasaki, 2007, Punding prevalence in Parkinson's disease, Mov Disord, 22, 1179, 10.1002/mds.21296 Giovannoni, 2000, Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies, J Neurol Neurosurg Psychiatry, 68, 423, 10.1136/jnnp.68.4.423 Pezzella, 2005, Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease, Mov Disord, 20, 77, 10.1002/mds.20288 Young, 2005, The role of dopamine in conditioning and latent inhibition: what, when, where and how?, Neurosci Biobehav Rev, 29, 963, 10.1016/j.neubiorev.2005.02.004 Dodd, 2005, Pathological gambling caused by drugs used to treat Parkinson disease, Arch Neurol, 62, 1377, 10.1001/archneur.62.9.noc50009 Giladi, 2007, New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset, J Psychopharmacol, 21, 501, 10.1177/0269881106073109 Driver-Dunckley, 2007, Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome, Clin Neuropharmacol, 30, 249, 10.1097/wnf.0b013e31804c780e Evans, 2007, Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis, Mov Disord, 22, 590, 10.1002/mds.21303 Quickfall, 2007, Pathological gambling associated with dopamine agonist use in restless legs syndrome, Parkinsonism Relat Disord, 13, 535, 10.1016/j.parkreldis.2006.10.001 Tippmann-Peikert, 2007, Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists, Neurology, 68, 301, 10.1212/01.wnl.0000252368.25106.b6 Voon, 2007, Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease, Arch Neurol, 64, 212, 10.1001/archneur.64.2.212 Mamikonyan, 2008, Long-term follow-up of impulse control disorders in Parkinson's disease, Mov Disord, 23, 75, 10.1002/mds.21770 Driver-Dunckley, 2003, Pathological gambling associated with dopamine agonist therapy in Parkinson's disease, Neurology, 61, 422, 10.1212/01.WNL.0000076478.45005.EC Kurlan, 2004, Disabling repetitive behaviors in Parkinson's disease, Mov Disord, 19, 433, 10.1002/mds.10625 Miwa, 2004, Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease, Parkinsonism Relat Disord, 10, 177, 10.1016/j.parkreldis.2003.08.002 Ardouin, 2006, Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation, Mov Disord, 21, 1941, 10.1002/mds.21098 Witjas, 2005, Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation, Mov Disord, 20, 1052, 10.1002/mds.20501 Fenelon, 2000, Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors, Brain, 123, 733, 10.1093/brain/123.4.733 Holroyd, 2001, Prospective study of hallucinations and delusions in Parkinson's disease, J Neurol Neurosurg Psychiatry., 70, 734, 10.1136/jnnp.70.6.734 Sanchez-Ramos, 1996, Visual hallucinations associated with Parkinson disease, Arch Neurol, 53, 1265, 10.1001/archneur.1996.00550120077019 Ravina, 2007, Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group, Mov Disord, 22, 1061, 10.1002/mds.21382 Chou, 2005, Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments, Clin Neuropharmacol, 28, 215, 10.1097/01.wnf.0000180228.77802.32 Inzelberg, 1998, Auditory hallucinations in Parkinson's disease, J Neurol Neurosurg Psychiatry, 64, 533, 10.1136/jnnp.64.4.533 Goetz, 2005, Hallucinations and sleep disorders in PD: six-year prospective longitudinal study, Neurology, 64, 81, 10.1212/01.WNL.0000148479.10865.FE Marsh, 2004, Psychiatric comorbidities in patients with Parkinson disease and psychosis, Neurology, 63, 293, 10.1212/01.WNL.0000129843.15756.A3 Dewey, 2000, Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease, Neurology, 55, 1753, 10.1212/WNL.55.11.1753 Factor, 1995, Parkinson's disease: drug-induced psychiatric states, Adv Neurol, 65, 115 Schrag, 2006, Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability, Parkinsonism Relat Disord, 12, 35, 10.1016/j.parkreldis.2005.06.011 Aarsland, 2000, Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study, J Am Geriatr Soc, 48, 938, 10.1111/j.1532-5415.2000.tb06891.x Goetz, 1993, Risk factors for nursing home placement in advanced Parkinson's disease, Neurology, 43, 2227, 10.1212/WNL.43.11.2227 Factor, 2003, Longitudinal outcome of Parkinson's disease patients with psychosis, Neurology, 60, 1756, 10.1212/01.WNL.0000068010.82167.CF Goetz, 1995, Mortality and hallucinations in nursing home patients with advanced Parkinson's disease, Neurology, 45, 669, 10.1212/WNL.45.4.669 Chou, 2006, Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs, Expert Opin Investig Drugs, 15, 339, 10.1517/13543784.15.4.339 Miyasaki, 2006, Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 66, 996, 10.1212/01.wnl.0000215428.46057.3d Parkinson Study Group, 1999, Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease, N Engl J Med, 340, 757, 10.1056/NEJM199903113401003 Pollak, 2004, Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up, J Neurol Neurosurg Psychiatry, 75, 689, 10.1136/jnnp.2003.029868 Fernandez, 2003, Long-term outcome of quetiapine use for psychosis among Parkinsonian patients, Mov Disord, 18, 510, 10.1002/mds.10374 Reddy, 2002, The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia, Mov Disord, 17, 676, 10.1002/mds.10176 Merims, 2006, Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis, Clin Neuropharmacol, 29, 331, 10.1097/01.WNF.0000236769.31279.19 Morgante, 2004, Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis, Clin Neuropharmacol, 27, 153, 10.1097/01.wnf.0000136891.17006.ec Ondo, 2006, Double-blinded, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease, Mov Disord, 20, 958, 10.1002/mds.20474 Rabey, 2007, Effect of quetiapine in psychotic Parkinson's disease patients; a double-blinded labeled study of 3 months' duration, Mov Disord, 22, 313, 10.1002/mds.21116 Breier, 2002, Olanzapine in the treatment of Dopamimetic-induced psychosis in patients with Parkinson's disease, Biol Psychiatry, 52, 438, 10.1016/S0006-3223(02)01392-6 Goetz, 2000, Olanzapine and clozapine: comparative effects on motor function in hallucination PD patients, Neurology, 55, 789, 10.1212/WNL.55.6.789 Ford, 1994, Risperidone in Parkinson's disease, Lancet, 344, 681, 10.1016/S0140-6736(94)92114-8 Rich, 1995, Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes, J Clin Psychiatry, 56, 556 Meco, 1997, Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study, Mov Disord, 12, 610, 10.1002/mds.870120423 Leopold, 2000, Risperidone treatment of drug-related psychosis in patients with Parkinsonism, Mov Disord, 15, 301, 10.1002/1531-8257(200003)15:2<301::AID-MDS1014>3.0.CO;2-2 Mohr, 2000, Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial, Mov Disord, 15, 1230, 10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9 Fernandez, 2004, Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience, Clin Neuropharmacol, 27, 4, 10.1097/00002826-200401000-00003 Friedman, 2006, Open-label flexible dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease, Mov Disord, 21, 2078, 10.1002/mds.21091 Emre, 2004, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med, 351, 2509, 10.1056/NEJMoa041470 Pearce, 1974, Amantadine hydrochloride: alteration in peripheral circulation, Neurology, 24, 46, 10.1212/WNL.24.1.46 Blackard, 1993, Edema−an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs, Am J Med, 94, 445, 10.1016/0002-9343(93)90160-Q Bianchi, 2005, Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease, Clin Neuropharmacol, 28, 245 Varsano, 2000, Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema, Respiration, 67, 580, 10.1159/000029576 Biglan, 2007, Risk factors for somnolence, edema, and hallucinations in early Parkinson disease, Neurology, 69, 187, 10.1212/01.wnl.0000265593.34438.00 Kleiner-Fisman, 2007, Risk factors for the development of pedal edema in patients using pramipexole, Arch Neurol, 64, 820, 10.1001/archneur.64.6.noc60158 Tan, 2000, Clinical characteristics of pramipexole-induced peripheral edema, Arch Neurol, 57, 729, 10.1001/archneur.57.5.729 Schrag, 1998, The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease, Clin Neuropharmacol, 21, 169 Holloway, 2004, Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial, Arch Neurol, 61, 1044 Olsen, 2006, Malignant melanoma and other types of cancer preceding Parkinson disease, Epidemiology, 17, 582, 10.1097/01.ede.0000229445.90471.5e Olsen, 2005, Atypical cancer pattern in patients with Parkinson's disease, Br J Cancer, 92, 201, 10.1038/sj.bjc.6602279 Zanetti, 2006, Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature, Melanoma Res, 16, 201, 10.1097/01.cmr.0000215043.61306.d7 Jansson, 1985, Low cancer rates among patients with Parkinson's disease, Ann Neurol, 17, 505, 10.1002/ana.410170514 Moller, 1995, Occurrence of different cancers in patients with Parkinson's disease, BMJ, 310, 1500, 10.1136/bmj.310.6993.1500 Skibba, 1972, Multiple primary melanoma following administration of levodopa, Arch Pathol, 93, 556 Kable, 1989, Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine, Cancer Res, 49, 2327 Fiala, 2003, Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?, Parkinsonism Relat Disord, 9, 321, 10.1016/S1353-8020(03)00040-3 Siple, 2000, Levodopa therapy and the risk of malignant melanoma, Ann Pharmacother, 34, 382, 10.1345/aph.19150 Constantinescu, 2007, Malignant melanoma in early Parkinson's disease: the DATATOP trial, Mov Disord, 22, 720, 10.1002/mds.21273 Olsen, 2007, Treatment with levodopa and risk for malignant melanoma, Mov Disord, 22, 1252, 10.1002/mds.21397 Frigerio, 2005, Education and occupations preceding Parkinson disease: a population-based case-control study, Neurology, 65, 1575, 10.1212/01.wnl.0000184520.21744.a2 Elwood, 1990, Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn, Int J Epidemiol, 19, 801, 10.1093/ije/19.4.801 Driver, 2007, A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease, Cancer Epidemiol Biomarkers Prev, 16, 1260, 10.1158/1055-9965.EPI-07-0038 Abbott, 1992, Diet, body size and micronutrient status in Parkinson's disease, Eur J Clin Nutr, 46, 879 Chen, 2003, Weight loss in Parkinson's disease, Ann Neurol, 53, 676, 10.1002/ana.10577 Uc, 2006, Predictors of weight loss in Parkinson's disease, Mov Disord, 21, 930, 10.1002/mds.20837 Beyer, 1995, Weight change and body composition in patients with Parkinson's disease, J Am Diet Assoc, 95, 979, 10.1016/S0002-8223(95)00269-3 Vardi, 1976, Weight loss in patients treated long-term with levodopa. Metabolic aspects, J Neurol Sci, 30, 33, 10.1016/0022-510X(76)90253-7 Lorefalt, 2004, Factors of importance for weight loss in elderly patients with Parkinson's disease, Acta Neurol Scand, 110, 180, 10.1111/j.1600-0404.2004.00307.x Markus, 1993, Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters, J Neural Transm Park Dis Dement Sect, 5, 117, 10.1007/BF02251202 Davies, 1994, A study of the nutritional status of elderly patients with Parkinson's disease, Age Ageing, 23, 142, 10.1093/ageing/23.2.142 Markus, 1992, Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity, Clin Sci (Lond)., 83, 199, 10.1042/cs0830199 Levi, 1990, Increased energy expenditure in Parkinson's disease, BMJ, 301, 1256, 10.1136/bmj.301.6763.1256 Toth, 1997, Free-living daily energy expenditure in patients with Parkinson's disease, Neurology, 48, 88, 10.1212/WNL.48.1.88 Lang, 1997, Neuropsychological and behavioral changes and weight gain after medial pallidotomy, Ann Neurol, 41, 834, 10.1002/ana.410410624 Ondo, 2000, Weight gain following unilateral pallidotomy in Parkinson's disease, Acta Neurol Scand, 101, 79, 10.1034/j.1600-0404.2000.101002079.x Vitek, 2003, Randomized trial of pallidotomy versus medical therapy for Parkinson's disease, Ann Neurol, 53, 558, 10.1002/ana.10517 Moro, 1999, Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease, Neurology, 53, 85, 10.1212/WNL.53.1.85